PT Phapros Tbk

PEHA

ID1000147507

Pharmaceuticals

End-of-day quote INDONESIA S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
348 ^IDR	+1.16%		+1.16%	-45.62%

17/05	PT Phapros Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
06/04	PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Several Entities Seek IPO In 2015

January 08, 2015 at 10:30 am IST

Several Indonesian entities intend to launch an initial public offering (IPO) in 2015. PT Medco Power Indonesia and PT. Tri Wahana Universal intend to launch an IPO for 15%-30% stake by the second quarter of 2015.

PT PP Properti and PT Waskita Beton Precast plans to launch IPO in 2015. PT Pelayanan Listrik Nasional BATAM and PT Phapros Tbk. will launch an IPO in the first half of 2015.

GMF AeroAsia, PT, PT Harapan Borneo International, PT. Asuransi Jiwasraya (Persero) and PT Perkebunan Nusantara VII (Persero) also plans to launch an IPO, however, the stakes to be sold, price and listing period are not known.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
PT GARUDA MAINTENANCE FACILITY AERO ASIA TBK	52 IDR	+1.96%	0.00%	8.9Cr
PT WASKITA BETON PRECAST TBK	24 IDR	+9.09%	+50.00%	7.17Cr
PT PEMBANGUNAN PERUMAHAN PROPERTI TBK	11 IDR	0.00%	-8.33%	4.19Cr

Latest news about PT Phapros Tbk

PT Phapros Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	06/04	CI
PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023	31/23/31	CI
PT Phapros, Tbk Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
PT Phapros, Tbk Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
PT Phapros, Tbk Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
PT Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
PT Phapros, Tbk Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
PT Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
PT Phapros, Tbk Reports Earnings Results for the Half Year Ended June 30, 2021	26/21/26	CI
Pt Phapros, Tbk Reports Earnings Results for the First Quarter Ended March 31, 2021	06/21/06	CI
Pt Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2020	06/21/06	CI
Pt Phapros, Tbk Reports Earnings Results for the Nine Months Ended September 30, 2020	26/20/26	CI
Pt Phapros, Tbk Reports Earnings Results for the First Quarter Ended March 31, 2020	30/20/30	CI
Pt Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2019	31/20/31	CI
Pt Phapros Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2019	30/19/30	CI
Pt Phapros, Tbk Reports Earnings Results for the Half Year Ended June 30, 2019	30/19/30	CI
Pt Phapros, Tbk Reports Earnings Results for the First Quarter Ended March 31, 2019	30/19/30	CI
PT Kimia Farma Tbk completed the acquisition of 56.77% stake in PT Phapros, Tbk from PT Rajawali Nusantara Indonesia for an enterprise value of IDR 1.4 trillion.	27/19/27	CI
Pt Phapros, Tbk Reports Earnings Results for the Full Year Ended December 31, 2018	20/19/20	CI
PT Kimia Farma Tbk signed a sale and purchase agreement to acquire 56.77% stake in PT Phapros, Tbk from PT Rajawali Nusantara Indonesia.	14/19/14	CI
PT Phapros, Tbk acquired an additional 35.22% stake in PT. Lucas Djaja.	30/18/30	CI

Chart PT Phapros Tbk

Duration

Period

More charts

Company Profile

PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PT PHAPROS TBK	-45.62%	1.79Cr
ELI LILLY AND COMPANY	+57.40%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.65%	36TCr
MERCK & CO., INC.	+15.29%	32TCr
ABBVIE INC.	+12.32%	30TCr
ASTRAZENECA PLC	+15.51%	24TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.04%	18TCr
PFIZER, INC.	+3.18%	17TCr

Other Pharmaceuticals

PT Phapros Tbk

Equities

PEHA

ID1000147507

Pharmaceuticals

Several Entities Seek IPO In 2015

Stocks mentioned in the article

Latest news about PT Phapros Tbk

Chart PT Phapros Tbk

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals